Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06588686 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06588686 · ClinicalTrials.gov record · last posted 2026-08-17

A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.

Name: A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. — clinical trial record (NCT06588686)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: ASPIRE

StatusActive, Not Recruiting

PhasePhase 2

SponsorVicore Pharma AB

Started2024-12-09

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com

Protocol amendment history 3 changes detected by DataLookout

2026-08-18

Trial sites reduced: 111 → 104 locations

2026-04-24

Trial status changed: Recruiting → Active, Not Recruiting

2026-04-24

Trial sites reduced: 117 → 111 locations

Trial Details

NCT Number	NCT06588686
Lead Sponsor	Vicore Pharma AB Collaborators: Population Services International
Conditions	Idiopathic Pulmonary Fibrosis (IPF)
Enrollment	378 participants
Start Date	2024-12-09
Primary Completion	2027-05 (estimated)
Study Completion	2027-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-17